Belantamab mafodotin (DrugBank: Belantamab mafodotin)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
28 | Systemic amyloidosis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04617925 (ClinicalTrials.gov) | December 2020 | 20/10/2020 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | AL Amyloidosis | Drug: Belantamab mafodotin | European Myeloma Network | GlaxoSmithKline | Not yet recruiting | 18 Years | N/A | All | 35 | Phase 2 | Greece |